Oncogenomics (PDF)

Contributors. Preface. Second I: Introduction. 1. At the Precarious Cusp of Oncogenomics (Charles Brenner). Second II: Molecular Profiling in Cancer: DNA, RNA and Protein. 2. Genome-Wide Searches for Mutations in Human Cancer (Michael R. Stratton, P. Andrew Futreal, and Richard Wooster). 3. Molecular Cytogenetics: Increasing Resolution Using Array-Based CGH (Anne Kallioniemi). 4. SNPs and Functional Polymorphisms in Cancer (Penelope E. Bonnen and David L. Nelson). 5. Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility (Therese Sørlie, Anne-Lise Børresen-Dale, Per E. Lønning, Patrick O. Brown, and David Botstein). 6. Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays (Mary B. Daly, Alicia Parlanti, and David Duggan). 7. Linking Drugs and Genes: Pharmacogenomics, Pharmacoproteomics, Bioinformatics, and the NCI-60 (John N. Weinstein). 8. Tissue Microanalysis: Profiling Cancer Stages (Michael A. Tangrea and Michael R. Emmert-Buck). 9. Proteomic s in Bladder Cancer (Julio E. Celis, Irina Gromova, Fritz Rank and Pavel Gromov). Second III: Model Systems. 10. Chemical and Genetic Methods to Validate Targets in Nonmammalian Organisms (Tia M. Maiolatesi and Charles Brenner). 11. Mouse Models of Cancer (Debrah M. Thompson, Louise van der Weyden, Patrick J. Biggs, Yeun-Jun Chung and Allan Bradley). 12. Genome-Wide Modifier Screens: How the Genetics of Cancer Penetrance May Shape the Future of Prevention and Treatment (Linda D. Siracusa, Karen A. Silverman, Revati Koratkar, Marina Markova and Arthur M. Buchberg). Second IV: Molecularly Targeted Drugs. 13. Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches (Paul Nghiem, Yong-son Kim and Stuart L. Schreiber). 14. Ras Superfamily-Directed Compounds (George C. Prendergast). 15. Clinomics: Post-Genomic Cancer Care (Daniel D. Von Hoff, Haiyong Han, and David Bearss). Part V: Conclusion). 16. Oncogenomics and the NCI Director's Vision

Charles Brenner is Director of the Cancer Mechanisms Program at Dartmouth's Norris Cotton Cancer Center in New Hampshire. He trained in yeast molecular biology with Anthony Brake at Chiron and yeast genetics with Kunihiro Matsumoto at DNAX before earning his Ph.D. in the biochemistry department at Stanford with Robert Fuller. In 1993, as a Leukemia Society Fellow, Brenner moved to Brandeis to train in X-ray crystallography with Gregory Petsko and Dagmar Ringe and then took an independent position at the Kimmel Cancer Center at Jefferson in 1996. Brenner rose to head the KCC's Program in Structural Biology and Bioinformatics in 2000 and joined Dartmouth Medical School's faculties of Genetics and Biochemistry in 2003. Dr. Brenner's research group uses genetics, enzymology and X-ray crystallography to dissect the cellular pathways perturbed by loss of the FHIT tumor suppressor gene, which is lost early in the development of many tumors of epithelial origin.

David Duggan received his Ph.D. in 1997 in Human Genetics at Pittsburgh and trained with Jeffrey Trent in microarray analysis of breast and prostate cancer from 1998 to 2000 at the National Human Genome Research Institute. Duggan then served as an associate investigator at the National Institute of Arthritis and Musculoskeletal and Skin Diseases until 2003 when he took his current position at the Translational Genomics Research Institute in Arizona. Dr. Duggan's laboratory uses SNP genotyping and microarray analysis to investigate the genetic basis of human diseases.

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.